A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 785 participants.
Also called NCT04179045
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 785 participants
- Sponsor
- Registry
-
NCT04179045
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04179045. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-01 (anticipated); primary completion 2022-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Condition
- Coronary Artery Disease
- Intervention (Device)
- The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Lead sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
- Collaborator
- CCRF Inc., Beijing, China
Record details
- Record id
cardio:ct-nct04179045- Content hash
16d740ecccfc1b87df54a86c536a13ef58c3523df2115559aa545985f9ad9bb8